Analytical Data
-
Gene name
CD79B
- Application
-
Alternative Names
CD79B；B29；IGB；B-cell antigen receptor complex-associated Protein beta chain
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P40259
-
Expression Region
29-159aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMARSEDR YRNPKGSACS RIWQSPRFIA RKRGFTVKMH CYMNSASGNV SWLWKQEMDE NPQQLKLEKG RMEESQNESL ATLTIQGIRF EDNGIYFCQQ KCNNTSEVYQ GCGTELRVMG FSTLAQLKQR NTLKD
-
Molecular Weight
18 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD79B is a vital component of the B cell receptor (BCR) complex, playing a central role in B cell development and activation. As a membrane protein, it acts alongside its counterpart CD79A to transmit signals upon antigen recognition, which is crucial for initiating adaptive immune responses. Mutations or alterations in CD79B have been associated with various hematological malignancies, including diffuse large B cell lymphoma (DLBCL) and other B cell neoplasms. This has spurred significant research interest in CD79B as a potential target for therapeutic intervention. Studies have shown that targeting CD79B, either through monoclonal antibodies or small molecule inhibitors, could enhance treatment efficacy and overcome resistance mechanisms in B cell cancers. Furthermore, understanding the signaling pathways mediated by CD79B can provide insights into novel approaches for immunotherapy and personalized medicine. Given its importance in B cell biology and disease pathology, the investigation of CD79B recombinant proteins is crucial for elucidating its function and developing targeted therapies. Research on CD79B continues to expand, highlighting its significance in both basic immunology and clinical applications.
